Silver Book Fact

Disease specific status and generic health status improvements from TAVR and SAVR

Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to 22 point improvement on a 100 point scale) and in generic health status (3.9 to 5.1 point improvement on a 36 point scale).

Baron S, Arnold S, Wang K, et al. Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Risk: Results from PARTNER 2 Randomized Clinical Trial. JAMA Cardiology. 2017; 2(8): 837-45. https://jamanetwork.com/journals/jamacardiology/article-abstract/2635358

Reference

Title
Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Risk: Results from PARTNER 2 Randomized Clinical Trial
Publication
JAMA Cardiology
Publication Date
2017
Authors
Baron S, Arnold S, Wang K, et al
Volume & Issue
Volume 2, Issue 8
Pages
837-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states